Enrollment complete in Unigene's oral PTH Phase 2 osteoporosis study in postmenopausal women

Unigene Laboratories, Inc. (OTCBB: UGNE) a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced today that the Company has completed patient enrollment of its Phase 2 study with an experimental oral parathyroid hormone (PTH) analog for the treatment of osteoporosis in postmenopausal women. Unigene is developing its oral PTH in collaboration with GlaxoSmithKline (GSK) as part of an exclusive worldwide licensing agreement. According to the agreement with GSK, Unigene will receive a $4M milestone payment for completion of Phase 2 patient enrollment.

“I am extremely impressed with the Unigene team's execution of this study in just four months since the signing of our collaboration with GSK, and believe this not only showcases our clinical trial expertise, but represents an important competitive advantage.”

Ashleigh Palmer, President and Chief Executive Officer of Unigene Laboratories, Inc., said, "The completion of enrollment in this Phase 2 study with our proprietary oral formulation of the recombinantly produced PTH analog is a significant development milestone for Unigene. We are thrilled to have achieved this goal and remain focused on advancing this program that we believe has the potential to address an important medical need." Palmer continued, "I am extremely impressed with the Unigene team's execution of this study in just four months since the signing of our collaboration with GSK, and believe this not only showcases our clinical trial expertise, but represents an important competitive advantage."